Enanta Pharmaceuticals (ENTA) Interest Coverage Ratio (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Interest Coverage Ratio came in at 1.54 in Q1 2026, up 89.23% YoY from 0.81 in Q1 2025, and up 57.78% on a QoQ basis from 3.65 in Q4 2025.
Enanta Pharmaceuticals (ENTA) Interest Coverage Ratio (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Interest Coverage Ratio data on file, last reported at 1.54 in Q1 2026.
- Quarterly Interest Coverage Ratio rose 89.23% year-over-year to 1.54 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 7.85 (down 200.54% YoY) and the FY2025 annual result came in at 0.6, up 94.23% from the prior year.
- Interest Coverage Ratio improved to 1.54 in Q1 2026, from 3.65 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 0.21 in Q2 2025 to a low of 18.38 in Q2 2023.
- A 5-year average of 5.3 and a median of 2.22 in 2025 frame the typical range for Interest Coverage Ratio.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio slumped 6335.9% — and 2024, when it jumped 96.11%.
- Tracing ENTA's Interest Coverage Ratio over 5 years: stood at 1.7 in 2022, then slumped by 496.15% to 10.14 in 2023, then increased by 22.8% to 7.83 in 2024, then surged by 53.37% to 3.65 in 2025, then surged by 57.78% to 1.54 in 2026.
- The last three Interest Coverage Ratio figures came in at 1.54 (Q1 2026), 3.65 (Q4 2025), and 2.22 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | -1.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.37 |
| Mar 31, 2026 | -1.54 |
| Dec 31, 2025 | -3.65 |
| Sep 30, 2025 | -2.22 |
| Jun 30, 2025 | -0.21 |
| Mar 31, 2025 | -14.31 |
| Dec 31, 2024 | -7.83 |
| Sep 30, 2024 | -12.31 |
| Jun 30, 2024 | -0.72 |
| Mar 31, 2024 | -1.03 |
| Dec 31, 2023 | -10.14 |
| Sep 30, 2023 | -4.71 |
| Jun 30, 2023 | -18.38 |
| Dec 31, 2022 | -1.70 |
| Jun 30, 2022 | -0.29 |
| Mar 31, 2022 | -0.41 |
| Dec 31, 2021 | -0.31 |
| Sep 30, 2021 | -1.15 |
| Jun 30, 2021 | -1.92 |
| Mar 31, 2021 | -1.01 |